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Abstract
Immune responses are qualitatively and quantitatively influenced by a complex network of receptor-ligand interactions.
Among them, the CD137:CD137L pathway is known to modulate innate and adaptive human responses against
Mycobacterium tuberculosis. However, the underlying mechanisms of this regulation remain unclear. In this work, we
developed a Bayesian Computational Model (BCM) of in vitro CD137 signaling, devised to fit previously gathered
experimental data. The BCM is fed with the data and the prior distribution of the model parameters and it returns their
posterior distribution and the model evidence, which allows comparing alternative signaling mechanisms. The BCM uses
a coupled system of non-linear differential equations to describe the dynamics of Antigen Presenting Cells, Natural Killer
and T Cells together with the interpheron (IFN)-c and tumor necrosis factor (TNF)-a levels in the media culture. Fast and
complete mixing of the media is assumed. The prior distribution of the parameters that describe the dynamics of the
immunological response was obtained from the literature and theoretical considerations Our BCM applies successively the
Levenberg-Marquardt algorithm to find the maximum a posteriori likelihood (MAP); the Metropolis Markov Chain Monte
Carlo method to approximate the posterior distribution of the parameters and Thermodynamic Integration to calculate the
evidence of alternative hypothesis. Bayes factors provided decisive evidence favoring direct CD137 signaling on T cells.
Moreover, the posterior distribution of the parameters that describe the CD137 signaling showed that the regulation of IFN-
c levels is based more on T cells survival than on direct induction. Furthermore, the mechanisms that account for the effect
of CD137 signaling on TNF-a production were based on a decrease of TNF-a production by APC and, perhaps, on the
increase in APC apoptosis. BCM proved to be a useful tool to gain insight on the mechanisms of CD137 signaling during
human response against Mycobacterium tuberculosis.
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Introduction
Tuberculosis is one of the earliest recorded human diseases that
still poses an unresolved global health problem. Mycobacterium
tuberculosis (M.tb), the causative agent of tuberculosis, results in 2
million deaths annually worldwide despite available treatment.
Furthermore, approximately one-third of the world population is
estimated to be infected with M.tb (WHO, 2010).
Although the immunological mechanisms against M.tb are not
fully understood, protective defense against mycobacterial infec-
tions is primarily mediated by the interaction of antigen-specific T
cells and macrophages [1,2]. This interaction often depends on the
interplay of cytokines produced by these cells.
Even though a wide spectrum of cytokines may contribute to
protection, a type 1 response, dominated by interferon (IFN)-c
secretion, is considered the main mediator of the protective
immunity against M.tb [2,3]. IFN-c activates macrophages to
become effector cells that express microbicidal substances and
cytokines, with tumor necrosis factor a (TNF-a) playing a funda-
mental role in controlling the mycobacterial infection [4–5]. While
the protective role of IFN-c in tuberculosis is well established [2]
[6], TNF-a exhibits a very complex network of interactions and
many of its functions are still not fully understood [7]. In spite of
the major role TNF-a plays a major role in controlling M.tb
infection, activating macrophages early during the immune
response and participating in granuloma formation [8,9], excessive
levels of TNF-a may cause tissue damage in vivo, including
hyperinflammation and caseous necrosis [7].
Several signaling proteins modulate the levels and pattern of
cytokines produced by immune cells upon M.tb antigen (Ag)
stimulation [10–12]. In particular, we have demonstrated a key
role of CD137 (4–1BB) in modulating human cytokine responses
against M.tb. CD137 is a TNFR related superfamily signaling
molecule that regulates the effector functions of most types of
immune cells [13,14]. We have previously shown that signaling
through the CD137:CD137 ligand (L) pathway interfered with
IFN-c and TNF-a secretion by innate immune cells, while
boosting T cell effector functions during tuberculosis [15].
However, these results did not provide a definite answer on the
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nature of the mechanisms of CD137 signaling. Therefore, we
sought to develop a Bayesian Computational Model (BCM) in
orfer to further our understanding of the mechanisms of this
pathway. This BCM allowed us to fit previously gathered
experimental data. By using the BCM we could predict the
dynamics of Antigen Presenting Cells (APC), Natural Killer (NK)
and T Cells together with the IFN-c and TNF-a levels in the
media culture. Bayes factors provided decisive evidence favoring
direct CD137 signaling on T cells. Futhermore, the posterior
distribution of the parameters that predicted that CD137
modulation on IFN-c levels is based more on its effect on T cell
survival than on direct induction of the cells. Besides, TNF-
a regulation by CD137 was based on a reduction in TNF-
a production by APC and, perhaps, on the increase in APC
apoptosis. BCM proved to be a useful tool to gain insight on the
mechanisms of CD137 signaling during human response against
Mycobacterium tuberculosis.
Classical immunology uses conceptual models to make predic-
tions and draw conclusions from experimental data, relying on the
expert criteria of the researcher. Computational models arise from
the formalization of those conceptual models and the expert
criteria in a set of defined rules operating on simplified
representations of the immunological process.
A BCM is meant to fit a set of actual experimental
measurements. The probability function of the experimental
observations is obtained using the error rate of the provided
measurements. BCMs formalize the link between a qualitative
hypothesis and experimental data. Our BCM applies successively:
1) the Euler method to solve the set of ordinary differential
equations (ODE) that model the system to predict the outcome of
the experiments, 2) the Square Sum of normalized residuals that
compare predicted and measured values to calculate the posterior
likelihood; 3) the Levenberg-Marquardt algorithm (LMA) to find
the parameter that maximizes the posterior likelihood; 4) the
Metropolis Markov Chain Monte Carlo method (MCMC) to
sample from the posterior distribution of the parameters and 4)
Thermodynamic Integration to calculate the evidence of alterna-
tive hypothesis about the signaling mechanism.
Here we present a parameterized BCM of a set of previous
experiments performed to investigate the CD137 signaling
pathway in tuberculosis and to gain an insight into the possible
mechanisms of this pathway.
Materials and Methods
Experimental Data
The experimental rationale consists in studying the role of
CD137 in the context of tuberculosis by using an anti-CD137
blocking monoclonal antibody (mAb) during proliferation, apo-
ptosis and cytokine production. Most of the experimental data
were from our previous work [15], with some additional kinetics
results included here.
Study Subjects
BCG vaccinated healthy adults (n = 40) with no history of
tuberculosis participated in the study. Quantiferon TB Gold In-
TubeH test (Cellestis INC, Valencia, CA, USA) was used to
differentiate true healthy donors (HD) from individuals with
latent tuberculosis, which were excluded from the study. HIV-
negative patients (n = 40) with active tuberculosis (TB) were
evaluated at the Hospital Mun˜iz (Buenos Aires, Argentina). The
diagnosis of tuberculosis was established based on clinical and
radiological data together with the identification of acid-fast
bacilli in sputum. All participating patients had received ,1
week of anti-tuberculosis therapy. Peripheral blood samples were
collected in heparinized tubes from all individuals after receiving
informed consent. The local ethical committee approved all the
studies performed.
Antigen
In vitro stimulation of cells throughout the present study was
performed with a cell lysate from the virulent M. tuberculosis H37Rv
strain (obtained through BEI Resources, NIAID, NIH: Mycobac-
terium tuberculosis, Strain H37Rv, Whole Cell Lysate, NR-14822)
prepared by probe sonication. The antigen (Ag) preparation is
indicated as ‘‘ M. tb Ag’’ throughout the manuscript.
Culture Conditions
PBMC were isolated by density gradient centrifugation on
Ficoll-Paque (Amersham Biosciences), resuspended in supple-
mented RPMI1640 and cultured (16106 cells/ml) in flat-bottom
24-welll or 96-well plates. In different experiments, cells were
incubated in the presence/absence of M.tb Ag (10 mg/ml). At
different times, CD137 and CD137L expression was determined
by flow cytometry. For blocking experiments, cells were
incubated 30 minutes with blocking mAbs (BD) against
CD137, CD137L, or isotype control. Then, cells were
stimulated with or without M.tb Ag. After 16 h, 4 or 5 days,
the percentage of IFN-c or TNF-a-secreting cells, lytic de-
granulation and apoptosis were determined by flow cytometry.
For proliferation determination, cells were pulsed with [3H]TdR
(1 mCi/well), harvested 16 h later and [3H]TdR incorporation
was measured in a liquid scintillation counter. In separate
experiments, mAbs anti-CD137 or anti-CD137L were added to
cells with or without the specific Ag. After 16 h, 48 h or 5 days,
IFN-c and TNF-a production was evaluated by ELISA
following the manufacturer’s instructions (eBioscience).
Flow Cytometry
In different experiments, PBMC were cultured with M.tb Ag 6
CD137 or CD137L blocking mAbs and stained for CD3, CD4,
CD8, CD56, CD14, CD137, CD137L expression using specific
mAbs (BD). Intracellular cytokine staining was also performed to
determine IFN-c and TNF-a (eBioscience) production at the
single-cell level as reported [16]. CD107a/b lysosome-associated
membrane protein-1/2 expression was used to measure CD8+ T
lymphocyte degranulation, as previously described [17]. In all
cases, negative control samples were incubated with irrelevant,
isotype-matched mAbs in parallel with the experimental samples.
For apoptosis analysis, after 5 days of culture, the percentage of
apoptotic/necrotic CD3+, CD3+CD4+ or CD3+CD8+ cells was
determined using the Annexin V-FITC Apoptosis Detection Kit I
(BD) following the instructions of the manufacturer.
Bayesian Computational Model
The parameterized BCM was developed for the prediction of
the previously described experiments. To build the BCM, we
identified the relevant elements of the biological process that are
needed to fit the experimental data based on the prior
knowledge of the system. We included only the variables for
which we have experimental data, excluding those cell types or
cytokines for which we have not. The Bayesian approach
implies that one must ‘‘forget’’ about the information present in
the results we want to fit. In this way, the amount of
information present in the experiments that was not present
in the prior information can be quantified.
Bayesian Model of CD137 Signaling in Tuberculosis
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Simulation of the Experimental Results and Calculation of
their Likelihood
The BCM is fed with the experimental data with their standard
errors and, for a given vector of parameters, it simulates the results
and calculates the vector of the normalized residuals. Each
normalized residual eyi is obtained by taking the difference
between the simulated and the experimental datum and dividing
it by the experimental measurement error:
eyi bð Þ~ yi bð Þ{yi
syi
ð1Þ
where yi(b) indicates the predicted value of the i
th observation as
a function of the parameter vector b(explained below); yi indicates
the actual measurement and syi indicates the standard error of the
ith measurement. The parameter likelihood is evaluated via:
logLik bð Þ~{ 1
2
: SSdata bð Þ{
Xn
i
log 2:p:syi
2
  ! ð2Þ
where, SSdata, the squared sum of the residuals, is defined as
SSdata bð Þ~
Xn
i
eyi bð Þ
 2
; ð3Þ
The predicted values arose from the numeric approximation of
a set of 17 nonlinear ordinary differential equations each one
describing the time evolution of a particular variable of the
idealized experimental system:
Lsi tð Þ
Lt
~fi s tð Þ,bð Þ ð4Þ
where b is a vector comprising 77 parameters. The system
variables include the number of cells in each state of the three
modeled cells types and the levels of cytokines and Ag. The initial
state of the system variables is also dependent on some
components of the parameter vector:
si 0ð Þ~hi bð Þ ð5Þ
This system of ODE equations (4) and the initial values of the state
variables (5) are presented in the Supporting Information
(Equations S1–S17 in Supporting Information S1). We took
special care in choosing the variables and parameters so that each
one represents an actual biological process. We only included one
phenomenological variable, the proliferation ratio, which repre-
sents the cell capacity of the system.
Additional equations are used to relate the system variables with
the expected value for each experimental data: the percentage of
receptor/ligand expression for the included types of cells, the levels
of IFN-c and TNF-ain the media culture, the percentage of IFN-c
and or TNF-a-secreting cells, the apoptosis for T-cells and the rate
of [3H]TdR incorporation by PBMC:
yi bð Þ~gi s ti,bð Þ,bð Þ ð6Þ
These equations are presented in Supporting Information S1
(R1–R14).
The ODE system of our BCM was constructed after the M.tb-
immune system model developed by Marino [18]. We included
NK cells and developed an approach for simulating co-stimulation
and competition for receptor binding between the ligand and the
anti-CD137 blocking mAb.
Simulations were performed for three different virtual treat-
ments: first, the ‘‘M.tb treatment’’; second, the ‘‘Blocking
treatment’’ (M.tb+a-CD137) and finally, the ‘‘Media treatment’’
(control experiments).
From the point of view of plausible reasoning, the prior
distribution of parameter values measures our knowledge (or
ignorance) about the system. Therefore, we used experimental
data obtained from different experimental contexts (including
several models in vivo and in vitro) and/or theoretical considera-
tions to determine the prior distribution of the BCM parameters
(Table S1 in Supporting Information S1).
Parameters that indicate the scale magnitude of some property
are better described after a logarithmic transformation, where
equivalent uncertainties of scale are represented by adding or
subtracting the same constant [19]. Alternatively, in the case of
parameters describing ratios (the ratio of each type of cells in
PBMC, the ratio of cells expressing the receptor, the ratio of cells
producing cytokines), we chose a slightly different transformation
to linearize uncertainty. We presumed that the mechanism
responsible for ratio, r, could be modeled as a first order
equilibrium constant, r = E/(1+E), hence E= r/(12r). Therefore,
for these parameters we applied a logit transformation, log(-
r)2log(12r). In both cases, we describe our ignorance of the exact
parameter values with a normal distribution of the logarithmic
transformation of the parameters. The normal distribution is the
probability density function that maximizes the entropy when only
the mean and variance are known [19].
The solution of the ODE system was numerically approximated
implementing the Euler method or the forth order Runge Kutta
method in C++. Each one of the differential equations S1–S17 in
Supporting Information S1 was approximated by assuming that all
the state variables remained constant during each time step. Time
steps of 6 seconds were used, since all the modeled biological
processes occur in longer time scales. As those time scales were also
longer that the mixing time of the system, we did not take into
account local variations in the concentrations of the different
components of the system. Instead, we approximated the evolution
of the system as if there were an instantaneous and complete
mixing of cells and cytokines. We modeled the evolution of a single
average value for each state variable. This approximation, taking
spatial structure out of the model, allowed for a considerable
reduction in computational time and coding efforts.
Our model included three types of cell populations: Antigen
Presenting cells (APC class), NK cells (NK class) and T cells (T
class). We have previously demonstrated that CD137 and
CD137L are both expressed on APC and NK cells, while only
CD137 is expressed in lymphocytes after in-vitro M.tb stimulation
[15]. To simplify the model, APC and NK are set to express the
ligand and receptor simultaneously on the same cell, since it was
reported that a receptor and ligand can be expressed on the same
innate immune cell [20–21]. However, the implication of a single
cell expressing both the ligand and the receptor and the immune
outcome of bidirectional signaling by CD137/CD137L are not
well understood [14]. Because the literature provides more
evidence for reverse rather than direct signaling in monocytes,
we only included the reverse signaling in these cells [22,23]. On
the other hand, we included only direct receptor signaling in NK
Bayesian Model of CD137 Signaling in Tuberculosis
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and T cells, as there is no evidence for reverse signaling in these
cell types. We modeled CD137 or CD137L signaling as a single
instantaneous event.
CD137L stimulation in human monocytes has been shown to
induce DC differentiation, with CD137L-DCs being more potent
in stimulating T cell responses in vitro than the classical DCs.
Taking into consideration these findings and the fact that we only
had experimental data in CD14+ cells, we captured monocytes,
macrophages and dendritic cells as a single APC population. Their
importance lies in that macrophages are the preferred habitats of
M.tb [24], and DCs are the major antigen presenting cells [25,26].
During a persistent infection such as tuberculosis, CD137 and
CD137L expression can be prolonged, therefore our model did
not describe receptor internalization [14].
Because our focus was on the cytokine responses, we only
included CD56bright natural killer cells (NKbright) as they are the
most efficient cytokine producers among NK populations [27].
Additionally, we excluded cytotoxic CD56dim natural killer cells
(NKdim) and CTL function in T cells. Finally, the entire T cell class
(TL) captures both the CD4 and CD8 proinflammatory T cell
subsets.
APC Dynamics
We described five different APC subpopulations (Figure 1,
Equations. S1–S5 in Supporting Information S1): resting (A0),
activated (Aa), activated and signalized through CD137 (As),
activated and bound to anti-CD137 blocking mAb (AAb), and
activated, signalized through CD137 and bound to anti-CD137
blocking mAb (As_Ab).
A0 includes circulating undifferentiated monocytes and imma-
ture dendritic cells. Upon interaction with M.tb, dendritic cells
undergo a number of phenotypical changes, a process termed
maturation [26]. TNF-a and IFN-c are also required for
macrophage activation by the antigen [28]. Therefore, in our
model the resting APC undergoes activation by the antigen uptake
in a TNF-a and IFN-c independent (DC, term K(AxAg)) or
dependent (monocytes, term K(AxAg)ac) manner. Thus, loss of A0
was modeled with the A0 antigen uptake and natural death at
a rate of mA0 (Equation (Eq.) S1 in Supporting Information S1).
We defined natural cell death as all processes that end up in cell
death with the exclusion of TNF-a dependent apoptosis. A small
A0 fraction expresses receptor and ligand and produces basal levels
of cytokines. This model included only classical macrophage
activation.
Eq.S2 in Supporting Information S1 describes the Aa dynamics,
showing a balance between APC Ag uptake (production of Aa),
natural death (mAa) and TNFa-induced apoptosis (maA). Since we
focused on CD137 signaling, the rate parameters describing
cytokine production, proliferation and apoptosis were defined for
two types of activated cells depending on whether they are
signalized by CD137 (As,As_Ab) or not (Aa, AAb).
CD137 is expressed by primary monocytes in an activation
dependent manner [29]. We assume that while all activated APC
express ligand and receptor and produce TNF-a, only a fraction
produce IFN-c. There have been previous works showing that
CD137 pathway induces activation, migration, survival, and
differentiation on monocytic cells (monocytes, macrophages, and
DCs) [23] [30]. However, it also seems likely that CD137 could
play different roles depending on the infecting bacterial species. In
fact, it has been proposed that CD137 plays opposite roles in
Gram-negative and Gram-positive bacterial infections [31].
Therefore, in our model the initial guess for induction of apoptosis
(ImA), and cytokine secretion (IaA IcA) by CD137 may be either
positive or negative.
Preliminary results using cultures of purified monocytes
stimulated with lysate of M.tb Ag, suggested that CD137 interacts
with CD137L, both expressed on APC, causing a decrease in
TNF-a secretion. It was also demonstrated that APC and NK
activate each other during human response against M.tb [32]
Thus, our model allows the interaction of ligand APC with NK
receptor. Eq.S3 in Supporting Information S1 describes As
dynamics. Once Aa population interacts with other APC or NK
cells expressing CD137, it becomes signalized be CD137 (As). If Aa
presents the antigen to a naı¨ve T cell, it can also become signalized
via CD137 as long as the interaction is not blocked by an
antibody. Traditionally, it was assumed that monocytes are unable
to proliferate; however, it has been shown that CD137 induces
a widespread proliferation of human peripheral monocytes [21].
Hence, we only allowed As to proliferate. The dynamics of these
cells also include natural death as well as TNF-a-induced
apoptosis.
Eq.S4 in Supporting Information S1 refers to AAb dynamics.
These cells come from CD137 receptor in Aa binding to the
blocking mAb. As they are involved in signaling, other term
parameters are the same as in Aa. Despite the receptor blockage,
these cells can be modulated by reverse signaling through the
antigen (As_Ab). As_Ab also comes from As that binds the anti-
CD137 blocking mAb (Eq. S5 in Supporting Information S1).
These populations use the same term parameters as As.
NK Dynamics
NK cell activity is regulated by a balance between the activating
and inhibitory receptors [33–34]. Early studies demonstrated that
mouse NK cell stimulation with cross-linking anti-CD137 anti-
bodies or with CD137L-expressing cells induced NK cell pro-
liferation and IFN-c secretion [35]. However, it was recently
demonstrated that CD137 is expressed by activated human NK
cells and that this interaction reduced NK-cell activation and IFN-
c production. Additionally, it was shown that impaired NK-cell
reactivity after CD137 triggering was not due to survival but
rather to inhibitory signals [36].
Two major subsets of NK cells have been recognized in
peripheral blood based on the differential expression of CD56
receptor [27]. The vast majority of circulating NK cells (CD56dim)
are cytotoxic and do not produce IFN-c. Only 5–10% of NK cells
are IFN-c producing cells (CD56bright). We have previously shown
that CD137 and CD137L are expressed only on CD56bright NK
cells [15]. Considering our analysis was focused on cytokine
modulation by CD137, we therefore included only the CD56bright
NK cells in our model.
Similar to APC dynamics, the model includes five NK cell
stages (Figure 2, Equations S6–S10 in Supporting Information S1):
resting (N0), activated (Na), activated with signaling though CD137
(Ns), activated and blocked (NAb) and activated with signaling and
blocked by anti-CD137 mAb (Ns_Ab).
CD56bright NK cell activation in tuberculosis requires IL12, NK
cell–APC interaction and M.tb–NK direct contact [37–38]. IL-12
is indirectly modeled through the presence of activated APC. As
shown in Eq. S6 in Supporting Information S1, the loss of N0 is
modeled as NK activation (rate k(N0,Na)A) and death (mN0). During
NK activation, NK-CD137:CD137L-APC interaction is possible,
but there is no actual evidence for this interaction. Thus, for the
sake of clarity and simplicity, we chose to include activation and
signaling in two separate steps. Additionally, because it was
demonstrated that the NK-NK interaction is possible and that NK
express both a ligand and a receptor, we incorporated this
interaction as well. Hence, Na dynamics (Eq. S7 in Supporting
Bayesian Model of CD137 Signaling in Tuberculosis
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Information S1) include CD137 signaling by APC or NK cells,
natural death, TNF-a induced-apoptosis and proliferation.
Eq. S8 in Supporting Information S1 describes Ns dynamics:
this population consists of Na signalized by the receptor. Eq. S9 in
Supporting Information S1 describes NAb, defined by the same
parameters that Na, but with the receptor bound to anti-CD137
blocking mAb. Equation S10 in Supporting Information S1
describes Ns_Ab which behaves as Ns, but with the receptor
blocked. We assumed that all activated NK cells produced IFN-c,
but only a fraction produced TNF-a and expressed ligand/
receptor pair.
T Lymphocytes Dynamics
T lymphocytes (TL) mediate adaptive immune responses that
play a vital role in the elimination of M.tb [39]. We modeled four
different T cells population: non-specific-antigen-T cells (Tns),
specific-antigen naı¨ve T cells (T0), activated and CD137 co-
stimulated cells (Ts) and activated T cells without CD137 signaling
(because of mAb blockage) (Tbl). (Fig. 3 Equations. S11–S14 in
Supporting Information S1).
Non-specific T cells, Tns, (Eq. S11 in Supporting Information
S1), the more numerous component of PBMC in vitro, were
included because their importance in the total cell count. Their
population proliferates at a rate of kT0 and dies at a rate of mT0.
T0 dynamics are described in the equation S12 in Supporting
Information S1. These cells proliferate and die at the same rate of
Tns, but can undergo activation/differentiation that depends on
the presence of activated APC (Aa, As, As_Ab and AAb). The rate of
activation was set to be independent from the CD137 receptor
blockage state. During activation, T cells express the receptor that,
depending on the concentration of anti-CD137 blocking mAb in
the media, can become blocked.
Extensive evidence has shown that signals through CD137
delivered by agonistic antibodies or by an overexpressed ligand
can augment T-cell activation or survival [40–43]. CD137 is not
expressed on resting T cells, but is induced by antigen (Ag)-
receptor signaling [41] [43–44]. Moreover, CD137 was proposed
as an effector T cell marker [45]. Thus, we postulated that all
activated TL express the receptor. Unpublished data from our lab
demonstrated that only 43.82% 61.63 and 23.95% 63.85 of
CD137+ TL are IFN-c+ and TNF-a+, respectively. Additionally,
we proposed that CD137 blockade in T cells induced apoptosis
and inhibited proliferation and cytokine production.
Figure 1. Diagram of APC dynamics in the in vitro culture. Five different APC subpopulations are described: resting (A0); activated (Aa);
activated and signaling through CD137 (As); activated and bound to anti-CD137 blocking mAb (Abl); and activated, signaling through CD137L and
bound to anti-CD137 blocking mAb (As_Ab). Rows indicate possible mechanisms for each subpopulation. Loss of A0 is modeled with A0 uptake of the
Ag (in the presence or absence of proinflammatory cytokines (macrophages and DC, respectively)) and death at a rate of mA0. A small A0 ratio
expresses receptor and ligand and produces basal levels of cytokines. Aa dynamics show the balance between APC uptake of Ag, natural death (mAa)
and TNF-a-induced apoptosis (maA). Once Aa interacts with other APC, NK or TL expressing CD137, signaling is initiated (As). As dynamics includes
proliferation, natural death and TNF-a induced apoptosis. AAb come from Aa receptor binding to blocking mAb. Although they have the receptor
blocked, these cells can be reverse signalized by the antigen (As_Ab). As_Ab also comes from As that bind the antigen. As we focus on CD137 signaling,
parameters (cytokine production, proliferation and apoptosis rates) define two types of activated cells, determined by signaling through CD137
(As,As_Ab) or not (Aa, AAb). We assume that all activated APC express ligands and receptors and produce TNF-a, but only a fraction produces IFN-c. The
initial estimation for the induction of apoptosis, proliferation and cytokine secretion by CD137 can be either positive or negative.
doi:10.1371/journal.pone.0055987.g001
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Equation S13 in Supporting Information S1 models Ts
dynamics, accounting for the differentiation of naı¨ve TL (T0),
proliferation (with a rate of kTs), natural death (mTs) and TNF-
induced apoptosis. Eq.S14 in Supporting Information S1 describes
Tbl cell dynamics, incorporating CD137 blockage, induction of
apoptosis, proliferation and IFN-c and TNF-a production. We
modeled apoptosis as occurring during time tA (time duration of
apoptosis); therefore, to predict the results of annexin binding, we
counted the cells that entered apoptosis in a time window of tA
before the measurement took place (Eq. R10, Supporting In-
formation S1).
Culture Media Dynamics
Cytokines are produced by a large variety of cells involved in
innate and adaptive immunity [46]. Because we measured IFN-c
and TNF-a levels in media and intracellular expression by single
cells in our experimental data, we modeled these two key cytokines
in tuberculosis.
Each equation has a degradation rate for each cytokine
represented by a m coefficient. TNF-a (Eq. S16 in Supporting
Information S1) is mainly secreted by activated APC (at a rate of
a-Aa). Because CD137 might have opposite roles in TNF-
a regulation during different bacterial infections [31], prior
estimates for the induction of TNF-a (a-IA) by CD137 included
both up (greater than one) and down (less than one) regulatory
effects. The antigen presence enhances TNF-a production by Aa.
Additionally, TL and NK cells can secrete TNF- a; however, prior
estimates indicated a low contribution from these cell types to the
total TNF-a levels.
Human NK cells are known to be a major source of early IFN-c
(modeled in Eq. S15 in Supporting Information S1) upon M.tb
stimulation in vitro [38]. In addition, prior estimates have
indicated that CD137 inhibits cytokine production by NK cells
[47]. On the other hand, macrophages were found to produce
small levels of IFN-c during M.tb responses [48]. Therefore, prior
estimates indicated that activated APC produced a small amount
Figure 2. Diagram of CD56bright NK cell dynamics in the in vitro culture. Five different NK subpopulations are described: resting (N0),
activated (Na), activated and signaling through CD137 (Ns), activated, signaling and blocked by anti-CD137 mAb (Ns_Ab) and activated and blocked
(NAb). Rows indicate possible mechanisms for each subpopulation. The loss of N0 is modeled as NK activation (rate k(N0,Na)A) and death (mN0). N0
activation (Na) requires IL12 (indirectly modeled as activated APC), activated APC and M.tb. The model includes activation and signaling in two steps.
Therefore, Na dynamics includes CD137 signaling by APC or NK cells, natural death, TNF-a induced-apoptosis and proliferation. Ns dynamics includes
IFN-c/TNFa induction by CD137 (IcN, IaN). NAb is defined by equations similar to Na, but with the receptor bound to anti-CD137 blocking mAb. Ns_Ab
behaves as Ns, but the receptor is also blocked. We assume that all activated NK cells produce IFN-c, but only a fraction produce TNF-a and expresse
ligand/receptor pair.
doi:10.1371/journal.pone.0055987.g002
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of IFN-c [49]. Once adaptive immunity has been fully developed,
IFN-c is mainly secreted by activated lymphocytes (cTS) [39].
CD137 enhances cytokine production by TL [50–51], thus, prior
estimates for the receptor blockage were biased to values less than
one.
When present, the antigen was modeled as being degraded with
a rate constant of mAg (Eq S17 in Supporting Information S1).
Tritiated Thymidine incorporation was calculated as the integral
of all cell type proliferations that occurred for the last 16 h (Eq.
R16). A scaling parameter wTym related this integral to the
measured Thymidine incorporation in cpm.
Posterior Likelihood Calculations
Prior probability of the tested parameters was calculated using
normalized residuals analogous to the ones defined in Eq 1. The
normalized residual corresponding to the jth parameter, ebj, was
calculated by taking the difference between the log or logit
transformed jth parameter bj and the expected value of the log or
logit transformed prior bj and dividing that value by the standard
deviation sbjof the log or logit transformed prior:
ebj bð Þ~
bj{bj
sbj
ð7Þ
The square sum of the normalized parameter residuals
definition is straightforward:
SSparam bð Þ~
Xk
j
ebj bð Þ
 2
ð8Þ
It was used to calculate the logarithm of the prior probability of
the tested vector b:
Figure 3. Diagram of TL dynamics in the in vitro culture. Four different TL subpopulations are described: non-specific-antigen-T cells (Tns),
specific-antigen naı¨ve T cells (T0), activated and CD137 co-stimulated cells (Ts); and activated T cells with blocked CD137 (Tb). Rows indicate possible
mechanisms for each subpopulation. Tn population only proliferates and dies. T0 dynamics also includes proliferation and natural death at the same
rate as Tn, and can undergo activation/differentiation (and became Ts or Tb) dependent on the presence of activated APC (Aa, As, As_Ab and AAb).
During activation, T cells express the receptor and, depending on the concentration of anti-CD137 mAb in the media, a portion of them can become
blocked. Prior estimates indicate that CD137 signals delivered by agonistic antibodies or by overexpressed ligands can augment T-cell activation or
survival. CD137 is not expressed on resting T cells, but rather is induced with antigen (Ag)-receptor signaling. Ts dynamics account for the
differentiation of naı¨ve LT0, proliferation, natural death and TNF-a induced apoptosis. Tbl dynamics incorporates apoptosis induced by CD137
blockage, inhibition and proliferation of IFN-c and TNF-a production. The model assumes that all activated TL express the receptor.
doi:10.1371/journal.pone.0055987.g003
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logPrior bð Þ~{ 1
2
:SSparam bð Þ{ 1
2
:
Xk
j
log 2:p:sbj
2
 
ð9Þ
The logarithm of the posterior Likelihood function (logPostLik)
results from taking the sum of the logPrior (Eq. 9) and the logLik
(Eq. 2):
logPostLik bð Þ
~{
1
2
: SSparam bð ÞzSSdata bð Þz
Xk
j
log 2:p:sbj
2
  
z
Xn
i
log 2:p:si
2
 !
ð10Þ
Levenberg-Marquardt Algorithm and Maximum
a Posteriori Likelihood
As only the square sums depend on the parameter vector, any
parameter vector that locally minimizes the total squares sum
(SStot = SSparam+SSdata) maximizes the a posteriori likelihood. Thus,
we implemented in C++ a multivariate nonlinear least squares
method, the Levenberg-Marquardt algorithm (LMA), to find MAP
candidates. At each step of the algorithm, a new value of the
transformed parameters’ vector, bnew, was calculated
bnew~boldz J
T:W:Jzl:diag JT:W:J
  {1: J:eð Þ ð11Þ
where J and W are the Jacobian and weights matrices; e is the
residual vector and l is the damping parameter. The elements of
the Jacobian matrix are the partial derivatives of the k transformed
parameters and of the n predictions measurements vector:
Jij bð Þ~
1 0viƒk, i~j
0 0viƒk, i=j
d{1: yð i0 b1,,bjzd,,bk
 
{yi0 b1,,bj ,,bk
  0vi0ƒn,i0~i{k
8>>><
>>>:
ð12Þ
A value of 1027 was used for the incremental coefficient d.
Elements of the weight matrix, Wij, and elements of the residual
vector, ei, are defined using equations 1 and 7:
Wij~
0 i=j
sbi
{2 0viƒk,i~j
syi0
{2 0vi0ƒn,i0~i{k
8><
>:
ei~
eb i 0viƒk
ey i0 0vi0ƒn,i0~i{k
( ð13Þ
Initially, the damping parameter l was set to 1000. At each
LMA iteration (Eq. 11) the square sum for the new parameter
vector was tested: when it diminished, l was reduced by a factor of
v (a value of 10 was used) and the new parameter vector was
accepted; otherwise v was enlarged by the same factor and the old
parameter vector was kept. The algorithm was run until either the
change in Square Sum was less than 1029 or 5000 iterations were
reached.
At the vicinity of each local minimum, the gradient should be
close to zero:
Vi?
LlogPostLik
Lbi
bMAPð Þ
~{
1
2
L SSdatazSSparameters
 
Lbi
bMAPð Þ
~0
ð14Þ
A small value in both l and in the gradient (found by the matrix
multiplication J:e) indicates that a local minimum and not a saddle
point was found.
We chose different initial parameter vectors sampled from their
prior distribution. Using the 2nd order Taylor expansion we obtain
an expression that approximates the logPostLik around its
maximum.
logPostLik bð Þ~logPostLik bMAPð Þ
z
1
2
b{bMAPð ÞTH b{bMAPð Þ
ð15Þ
where, H is the Hessian matrix, the second order derivatives of the
logPosteriorLik:
Hij bð Þ~ LlogPostLikL log bið ÞL log bj
  bð Þ ð16Þ
Using eqs 10, 8, 7, 3 and 1, applying the chain rule, and neglecting
the 2nd order derivative we obtain the following approximation for
the Hessian:
Hij bð Þ&
Xn
i0
1
syi0 2
Lyi0
:L log bið Þ
bð Þ: Lyi0
L log bj
  bð Þzdij 1
sbi
2
ð17Þ
where dij equals one when i = j and zero otherwise. This Hessian
approximation can be also expressed in terms of the Jacobian and
weight matrices (eq 11 and 12):
H&JT:W:J ð18Þ
The inverse of the Hessian matrix approximates the covariance of
the posterior distribution of the parameters, S
post
b ~H
{1.
The probability of finding the global MAP increases with the
number of LMA runs.
bMAP~ argmaxPosteriorLikelihood bð Þ ð19Þ
We performed 5000 different optimizations starting each one on
a different initial value for the parameter to be fitted. The initial
conditions were chosen using random samples from the prior
distribution.
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Sampling the Posterior Distribution using Metropolis
Monte Carlo Markov Chain
By using Metropolis Monte Carlo Markov Chain method we
obtained a series of samples from the posterior likelihood, we then
estimated the credible intervals (CI) of the parameters and by
running simulations on the sampled parameters we obtained the
predictive posterior intervals (PPI) of the simulated data. CI and
PPI are analogous to the confidence intervals of frequentist
statistics. For example, in an experiment that determines the
uncertainty distribution of parameter p, if the probability that lies
between ‘a’ and ‘b’ is 0.95, then a,p,b is a 0.95 CI or PPI.
Metropolis MCMC method intends to sample from a target
distribution by performing a random walk over the entire space of
parameters. This random walk is governed by a Markov Chain
where the ratio of the transition probabilities between points in the
parameters space has to be equal to the ratio of the parameters’
probabilities. By setting proper transition probabilities we guar-
antee that, in the long run, we are sampling from the target
distribution. Metropolis MCMC set the transition probability to be
equal to the composition of an arbitrary symmetric jumping
distribution and an acceptance probability that contains the actual
information about the target distribution. However, the velocity of
the convergence of the random walk is dependent on an
appropriate selection of the jumping distribution.
We used a multivariate normal as the jumping distribution. The
covariance of this distribution was set to be equal to the inverse of
the Hessian approximation at the MAP multiplied by a constant
factor. This factor was empirically adjusted so the acceptance ratio
was roughly 20%. A factor of 0.02 was found to comply. To avoid
excessive sample correlation we stored one every 231 MCMC
steps (3 times the number of parameters).
Calculating the Evidence and Bayes Factors
The use of Bayes factor for model comparison remains valid
under less stringent conditions than other commonly used
comparison tools like the likelihood ratio test (LRT), which rests
on the assumption that the error in the parameter’s estimation
follows a normal distribution. Bayes factors integrate prior
information (which has to be stated on the prior distribution of
the parameters) and place a penalty for placing too much model
structure, in this way it guards against over-fitting. However, they
are difficult to calculate, since marginalization involves integrating
the posterior likelihood over the multidimensional space of
parameters values. Bayesian model comparison depends on
estimating the model Evidence, which is defined as the probability
of obtaining the data given that the model is true and given the
prior information available about the parameters of the model.
Formally, we marginalize the parameters b of the model Mi:
Evidence(Mi)~P DDMið Þ
~
ð
b
P DDb,Mið Þ:P bDMið Þ:db
~
ð
b
PostLik bð Þ:db
ð20Þ
The model evidence can be used to compare the support the
data gives to alternative models through the calculation of Bayes
factors, which is the ratio of the evidences of the different models:
BayesFactor0,1~
Evidence M0ð Þ
Evidence M1ð Þ ð21Þ
The value of the Evidence provides an absolute measure of the
capability of the model to predict that data, irrespective of the
number of parameters but depending on the prior information
about them. To numerically approximate this integral we used
a MCMC based method, Thermodynamic Integration [52], which
builds a continuous and differentiable path of un-normalized
distributions, qa, between the prior and the un-normalized
posterior (the posterior likelihood):
qa bð Þ~ P DDb,Mið Þð Þa:P bDMið Þ ð22Þ
At a= 0, qa is the prior; at a= 1, qa is the posterior likelihood.
The logarithm of the Evidence can be obtained by taking the
expected value of the logLikelihood sampled along this path (see
deduction in [52])
logEvidence~
ð1
0
Ea logLik bDMið Þ½ da ð23Þ
where Ea is the expectancy under qa distribution. This integral can
be numerically solved by dividing the a path in N sections, a= (1/
N, 2/N,… N/N) and running a Metropolis MCMC for the qaj
distribution (eq. 22) at each aj value. Each MCMC run started at
the last sample of the previous run. MCMC settings were the same
as above except for the covariance of the jumping distribution. We
used the product of the same constant factor (0.05) and the inverse
of the Hessian approximation of the corresponding qa,
Hij bð Þa&a:
Xn
i0
1
syi0 2
Lyi0
:L log bið Þ
bð Þ: Lyi0
L log bj
  bð Þzdij 1
sbi
2
ð24Þ
At a= 1, Eq 18 reduces to Eq. 17.
Results
BCM Adequately Fits All Experimental Data
We fed the BCM with an experimental series acquired during
an already published study [53], with the addition of some
unreported data. We also fed the BCM with the prior distribution
of the parameters. Then, we took 5000 samples of the prior
distribution and started a LMA from each one. Three times, after
287–807 iterations, LMA reached a value of 60.67 for SStotal, the
minimum value we reached, corresponding to SSdata 35.17 and
SSparam 25.50, with a gradient norm of 0.02–0.002 and a l value
of 0.02 or lower. The difference in the parameters values was less
than 1 in 3000, indicating that the same minimum was reached
the three times. To check the validity of the Euler method we
solved the ODE system with the forth order Runge Kutta method
for this minimum. Both methods differed less than 0.36% in the
prediction of data. We only use Euler method from this point on.
Afterwards, we started 10 Metropolis MCMC runs at this
minimum, taking 10000 samples of the posterior distribution of
the model parameters at each run. The posterior distribution of
the predicted data, which we will describe in the following sections,
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is shown in Figures 4, 5, 6 and the posterior distribution of the
parameters in Figure 7 and Figures S1, S2, S3, S4, S5, S6, S7, S8,
S9, S10.
We solved the ODE system with both the Euler method and the
forth order Runge Kutta method for this minimum. We found that
the predictions of the model using Runge Katta differed less than
0.36% from the predictions of the Euler method; therefore we
decided to only use the latter for from this point.
Expression Profile of CD137 in Innate and Adaptive
Immune Cells
The timing of CD137:CD137L interactions and their effects on
the immune cells may depend on the availability and induction of
the ligand and receptor during the immune response [14].
Therefore, we studied the CD137 expression profile in the innate
and adaptive immune cells during in vitro responses against
tuberculosis. We measured the receptor expression in CD14+
monocytes, CD56bright NK cells and CD3+ T cells using flow
cytometry at different times after M.tb antigen stimulation.
Minimal CD137 levels were measured on the surface of the three
types of cells without stimulation. Overnight M.tb antigen
stimulation induced CD137 expression on CD14+ cells
(Figure 4A). Moreover, significant levels of CD137 were still
detected on monocytes after 5 days. BCM simulation was able to
fit this pattern and predicted a very distinctive profile. It predicted
that CD137 takes 11 h to double its basal expression but only 4 h
more to double it again. The expression was predicted to peak 30–
35 h after the stimulus and gradually declined, taking 47 more
hours to reach half the peak levels. After 120 h, the expression
levels were still double the basal levels.
Flow cytometry also detected significant percentages of CD137
on CD56bright NK cells at 24h of M.tb Ag stimulation, while only
basal receptor levels were detected at 120 h. Data from the BCM
simulation predicted that the peak occurred at 28 h, almost at the
measurement time (Figure 4B). Simulations demonstrated an even
longer delay than in APC, taking 17 h to double the basal levels
and approximately 3 h to duplicate them again. In contrast, APC
cells were predicted to return quickly to the basal levels, taking
only 21 h to reduce the expression to two times the basal levels;
fifteen hours later, the expression was only 10% higher than the
basal levels, denoting an early role for these cells during in vitro
immune response to M.tb.
The dynamics of CD137 expression was opposite in T
lymphocytes (Figure 4C). Cytometry measurements displayed no
significant increases in CD137 at 16 or 24 hours. However, after
120 h of stimulation with M.tb Ag, a 10-fold increase from the
basal CD137 expression levels was measured in T lymphocytes. In
the simulation, it takes`57 hours to double the basal levels, which
thereafter continue augmenting until 120 h.
Role of CD137 Pathway in Cytokine Modulation
Cytokines display a crucial role during the host immune
response against M.tb. Thus, we investigated the role of CD137
pathway on cytokine modulation. These experimental results were
previously published in [15]. Briefly, the results demonstrated that
blocking CD137:CD137L pathway significantly augmented TNF-
a production in tuberculosis patients at 16, 48 and 120 hours.
BCM simulations could also successfully fit this pattern.
Predicted TNF-a levels in media during ‘‘M.tb treatment’’
(Figure 5A) present a delayed growth initiation followed by an
exponential growth. Because the initial levels were set as zero, they
could not be compared, so we compared the predicted cytokine
levels at paired time points with or without M.tb stimulation (M.tb
treatment and media treatment, respectively). After 9 hours of M.tb
stimulation, the simulated TNF-a levels were doubled compared
to the levels obtained with media treatment. Subsequently, TNF-
a levels doubled 4 times during the following 9 hours. Predicted
TNF-a levels reached a peak 22 hours after the stimulation.
However, the levels diminished to approximately 50% of the
maximal peak value by the end of the experiment.
Simulations predicted that blocking CD137 reduced the delay
in TNF-a production. Accordingly, it predicted it only takes 3 h
during the blocking treatment to double the TNF-a levels obtained
with media treatment, doubling 5 more times in the 11 h
thereafter. The levels peaked at 18 h, gradually diminishing
thereafter to 50% of the peak value at the end of the experiment.
Additionally, we modeled IFN-c production in PBMC. In line
with our previous data, simulations demonstrated that blocking the
Figure 4. Fitting of the model (CD137/CD137L expression) to the data. A, Expression of CD137/CD137L in APC. B, Expression of CD137/
CD137L on NK. C, Expression of CD137 on TL. Curves represent the best fit of our mathematical model to the data. The median and the 50% of the
predictive posterior interval are shown. Means of experimental data are shown by triangles, error bars indicate the SEM from each group (7
individuals). Experimental data were obtained from PBMC of tuberculosis patients stimulated with M.tb Ag for 0, 16 and 120 h (A), 0, 24 and 120 h (B)
or 0, 16, 24 and 120 h (C). CD137 expression was determined by flow cytometry. The cytometric analysis was performed by first gating on monocytes
by light scatter and then gating on CD14+ cells (A), or by first gating on lymphocytes by light scatter and then on CD32CD56bright for NK cells (B) or
on CD3+ for T lymphocytes (C). Predictions were made according to the following equations (Supporting Information S1): A: R4, B: R8, C: R10.
doi:10.1371/journal.pone.0055987.g004
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Figure 5. Role of CD137:CD137L pathway in the cytokine microenvironment during human tuberculosis. A,B; Fitting of the data model
(cytokines in media). Curves represent the best fit of our mathematical model to the data. The median and the 50% of the predictive posterior interval
are shown. Means of experimental data are shown by triangles 6 SEM from each group (7 individuals). Experimental data were obtained from PBMC
of tuberculosis patients stimulated with or withoutM.tb Ag in the presence or absence of CD137 blocking mAb. After 16 h (ON), 2 days or 5 days, cell-
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CD137 pathway significantly augmented IFN-c production after
16 h (ON) of M.tb stimulation (Figure 5B). However, the blockage
of CD137 decreased IFN-c secretion after 2 and 5 days of antigen
stimulation (Figure 5B). With Ag treatment, IFN-c levels were
predicted to increase to double the levels without stimulus at 3 h.
Figure 5C prediction reveals that blocking CD137 results in
accelerated an TNF-a production rate in APC, denoting a role of
CD137 in changing the timing of the TNF-a response to M.tb.
These curves share with those of TNF-a levels in media an initial
exponential growth. Simulations demonstrated that neither NK
nor TL produced significant levels of TNF-a. Figure 5D shows the
NK and TL kinetics of the IFN- c production rate. In line with the
literature, our model predicts that IFN- c is produced early by NK
cells, with T cells acting as the major producers of this cytokine
after the initial 26–35 h. APC were not observed to produce
significant IFN-c levels.
To validate the model, we measured TNF-a and IFN-c
production by PBMC stimulated with M.tb for 24 hours with or
without anti-CD137 blocking antibodies, New experimental data
presented no contradiction with the simulations (Fig. 5C).
Intracellular Expression of Cytokines, Role of CD137
Our previous results [53] indicated that CD137:CD137L
interactions might induce distinct effects on cytokine secretion in
different cell types during the initial and later phases of the
immune response. As shown in Figure 4A and 4B, CD137
blockade strikingly augmented the percentage of specific
CD14+TNF-a+ and CD14+IFN-c+ cells in ON responses to
M.tb. Here, we provided previously unpublished results showing
that CD137 blockade enhanced CD14+TNF-a+ and CD14+IFN-c
percentages at 5 days of M.tb treatment. Furthermore, BCM
simulation once again fit the experimental results.
Additionally, CD137:CD137L pathway blockage augmented
the number of CD32CD56bright TNF-a+ and CD32CD56bright
IFN-c+ NK cells in response to M.tb (Figure 6C and 6D).
Simulation also predicted that the percentages of NK+TNF-a+ and
NK+IFN-c+ peak early during CD137 blockade.
Next, we investigated whether CD137:CD137L interactions
regulated the percentage of IFN-c and/or TNF-a producing
lymphocytes. As shown in Figure 6E and 6F, CD137 blockade
strikingly diminished the percentage of specific IFN-c/TNF-
a producing lymphocytes. Simulations predicted a slow exponen-
tial growth of the cytokine producing cells during the experimental
time course.
Additional Fitted Data
We included additional data related to the effect of CD137
blockage in our BCM analysis. M.tb Ag-stimulated PBMC
proliferation ([3H]TdR incorporation) was decreased by CD137
blockage. Our BCM fit the measured [3H]TdR incorporation on
all treatments. For media treatment the values compared were
2356–4675 cpm (0.25–0.75 confidence interval of the experimen-
tal data) vs. 3933–4914 cpm (0.25–0.75 posterior predictive
interval obtained from simulations); for M.tb treatment: 12600–
15700 cpm (experimental) vs. 11710–13331 cpm (simulations),
blocking treatment [M.tb+anti-CD137 mAb]: 1414–9976cpm
(experimental) vs. 374–11105 cpm (simulations). The effect of
the blockage on the percentage of TL apoptosis (measured by
cytometry) was also adequately fit: (media treatment: 11.3–21.8%
CD3+ Annexin V+ [experimental] vs. 11.3–15.0% CD3+ Annexin
V+ [simulations]; M.tb treatment: 24.3–30.9% CD3+ Annexin V+
[experimental] vs. 28.3–31.5% CD3+ Annexin V+ [simulations];
blocking treatment: 38.2–48.1% CD3+ Annexin V+ [experimen-
tal] vs. 36.7–42.1% CD3+ Annexin V+ [simulations]). A rough
estimate of the cell number (5.00E5–1.50E6 cells for all times and
treatments,) was also included in the BCM: (simulated data in
media treatment: 24 h 7.30E5–8.85E6cells; 120 h: 7.38E5–
9.82E6 cells; in M.tb treatment: 24 h: 7.28E5–8.81E6 cells
120 h: 8.85E5–1.17E6 cells; in blocking treatment 24 h;
7.25E5–8.78E6 cells 120 h; 7.88E5–1.04E6 cells).
Reduction in Model Parameters Uncertainty
BCM analysis of the experimental data reduced the uncertainty
in the model parameters’ values (Figures 7, S1, S2, S3, S4, S5, S6,
S7, S8, S9, S10). The total prior distribution volume (measured as
the logarithm of the covariance matrix determinant) was 16.4 dB.
The posterior distribution volume was reduced to 2962 dB, an
average reduction of 12.5 dB per parameter. The average
reduction in the variance of each parameter was of 6.91 dB, the
difference between both reductions indicating a sizeable correla-
tion between the parameters. Therefore, on average, the
logarithmic range of each parameter was reduced by a factor
2.21 (3.46 dB). This reduction was not homogeneous: no changes
occurred in 7 parameters, negligible reduction (less than 1 dB) in
21 parameters, moderate reduction (between 1 and 5 dB) occurred
in 31 parameters and, finally, substantial reduction (between 5 and
14 dB) was observed in 22 parameters.
A reduction in the parameter distribution range indicates that
the BCM successfully extracted from the data information that was
not present in the prior. For certain parameters, it would be
possible to extract the experimental information without this
sophisticated model. For instance, the parameter rRLN0 (which
suffered a reduction of 10 dB in its uncertainty) can be directly
obtained from the Receptor/Ligand measurement in resting NK
cells; a similar procedure could be applied to all ratios of resting
cells. However, in most other cases (k(AxN), aIAa, kIT), the
parameter depends on the data in a very complicated manner,
requiring the application of BCM (or an equivalent approach) to
extract the values.
An absence of range reduction is indicative of a poorly defined
parameter, which is not surprising given that there are more
parameters than data. A negligible reduction indicates that the
experimental data contained little information about the param-
eter range. In certain cases (e.g., aN0, aNa, cAa), the data
contained no information about the parameters because the
parameter influence on the data was negligible or because the
effect on the data was confounded by other parameters. In other
cases (e.g., cIN, rA, tAp), the parameter effect was sizeable but as
free supernatants were collected and assayed for TNF-a (A) and IFN-c (B) production by ELISA. The mean 6 SEM (15 individuals) of IFN-c and TNF-
a secretion levels is shown for each time. C, Predicted kinetic profile of instantaneous TNF-a production rate by total APC according to the BCM; the
median and the 50% of the predictive posterior interval are shown. D, Simulation kinetics profile of instantaneous IFN-c production rate by total NK
and total TL; the median and the 50% of the predictive posterior interval are shown. Predictions were made according to the following equations
(Supporting Information S1): A: S16 in Supporting Information S1, B: S15 in Supporting Information S1, C: S159 in Supporting Information S1, D: S1699
in Supporting Information S1 and S16999 in Supporting Information S1. New experimental data was included to validate the model. Levels of TNF-
a and IFN-c produced by PBMC stimulated with M.tb6 a-CD137 for 16 and 24 hours were measured by ELISA. IFN-c and TNF-a levels of the new data
was normalized as following: Normalized data = new data* old mean of M.tb treatment at 16 h/new mean of M. tb treatment at 16 h. Normalized
data is shown by bold triangles.
doi:10.1371/journal.pone.0055987.g005
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there was substantial prior knowledge, the new data provided little
additional information.
Those parameters that showed no reduction in the posterior
range might be unidentifiable and they can be removed from the
model without sizeable consequences. It is interesting to note that
we were able to defer the responsibility of choosing the minimum
set of parameters to the Bayesian Computational Model. We
consider that this is an advantage of the BCM approach: in case of
doubt one can incorporate a parameter to the model and still be
able to predict the data and draw meaningful conclusions,
although with the cost of a possibly quadratic increase in the
computational time.
Insight into the Response Dynamics and CD137
Mechanism
The effect of CD137 on cytokine production, proliferation and
apoptosis rates is described by 9 parameters. Prior and posterior
distributions of these parameters are shown in figure 7. In three
cases (cIA,cIN and aIN) there is a close match between the prior
and posterior distribution, indicating that the experimental series
provides negligible information about the existence of these
mechanisms. Using the Bayesian confidence interval method we
calculated the probability that each one of the remaining
parameters is greater or smaller than one (a value that indicates
no CD137 effect). In the case of T cells, the regulation of IFN-c
production was found to be based more on the effect of CD137 on
the survival of T cells (p(mIT,1),0.00001 and
Figure 6. Effect of CD137:CD137L pathway on the immune cell cytokine production in tuberculosis. Different curves represent the best
fit of our mathematical model to the data, the median and the 50% of the predictive posterior interval are shown. The mean of the experimental data
is shown by triangles. Experimental data were obtained from PBMC of tuberculosis patients stimulated with M.tb Ag in the presence or absence of
blocking anti-CD137 mAb. A–B; After 16 and 120 h, the intracellular expression of TNF-a (A) and IFN-c (B) was determined by flow cytometry, by first
gating on monocytes by light scatterand then by gating on CD14+ cells. Each represents the mean 6 SEM of the percentage of CD14+cytokine+ cells
for each group (11 individuals). C–D; PBMC were stimulated with M.tb Ag for 24 h in the presence or absence of blocking anti-CD137 mAb and
intracellular TNF-a (C) and IFN-c (D) expression on CD56bright NK cells was determined by flow cytometry by first gating on lymphocytes by light
scatter, then by gating on CD32 cells and finally gating on CD56bright NK cells. Each triangle represents the mean 6 SEM (10 individuals). E–F; PBMC
were stimulated with M.tb Ag for 4 days in the presence or absence of anti-CD137 blocking mAb. Intracellular TNF-a (E) and IFN-c (F) expression was
determined by flow cytometry in T cells. Each triangles represents the mean 6 SEM (16 individuals). Predictions were made according to the
following equations (Supporting Information S1): A: R3, B: R2, C: R7, D: R6, E: R12, F: R11.
doi:10.1371/journal.pone.0055987.g006
Figure 7. Reduction in the uncertainty of model parameters that describe the CD137 induction on cytokine production,
proliferation and apoptosis rates. Bayesian analysis on the experimental data reduced the uncertainty of the BCM parameter values. Light gray
areas represent the prior parameter distribution. Black areas represent the posterior parameter distribution. cIA (Induction factor of IFN-c production
by CD137::CD137L of APC), aIA (Induction factor of TNF-a production by CD137::CD137L of APC), mIA (Induction of death by CD137::CD137L of APC),
cIN (Induction factor of IFN-c production by CD137::CD137L of NK), aIN (Induction factor of TNF-a production by CD137::CD137L of NK), cIT
(Induction of IFN-c production by CD137), aIT (Induction of TNF-a production by CD137), mIT (Induction of apoptosis rate by CD137), kIT (Induction of
proliferation rate by CD137).
doi:10.1371/journal.pone.0055987.g007
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p(kIT.1),0.00001) than on IFN-c induction (cIT). There was
a huge reduction in the uncertainty of this last parameter, but with
the posterior distribution centered on an induction value of one.
On the other hand, the effect of CD137 on TNF-a levels appeared
to be related to a direct inhibitory effect on TNF-a production by
APC (p(mIA .1),0.005 ) and, perhaps, to APC survival
(p(mIA,1),0.06).
Comparing Models using Thermodynamic Integration
In our BCM, we modeled a direct CD137signaling effect in T
cells. However, an alternative mechanism that also explains the
late increase in IFN-c through an indirect effect is possible. As
blockage of the CD137/CD137L pathway increases TNF-a pro-
duction by in vitro cultures of PBMC stimulated with M.tb Ag, it is
possible that these higher TNF-a levels promote T cell apoptosis
and, in consequence, diminish cell proliferation and cytokine
secretion to a greater degree when compared to a direct CD137
blockade in T cells. To determine which of the competing
mechanism is supported by the data, we compared the original
model (‘‘direct model’’) with a new model where direct T cell
signaling was absent (‘‘indirect model’’). This new BMC, of 73
parameters, was able to fit most of the experimental data, although
not as precisely as the direct model, but it could not fit the CD137
blockade effects on IFN-c production (Figure 8) and T cells
survival. For this model, simulations predicted, for the percentages
of T cells undergoing apoptosis, the following values: Mt.b
treatment: 28.90–37.58%CD3+ Annexin V+, blocking treatment:
24.40–35.85%CD3+ Annexin V+. For. [3H]TdR incorporation:
Mt.b treatment: 10855.7–15341.1 cpm, blocking treatment:
9527.9–14729.4 cpm.
The SStotal of the indirect model global minimum for 5000
starting points was 84.79, 24.12 units more than the SStotal of the
direct model. We therefore calculated the Evidence of both models
by Thermodynamic Integration. The evidence of the direct model
was 228461.68, while the indirect model evidence was
2294.1060.68. The difference between both evidences, 10.07,
corresponded to a Bayes factor of 43.7 dB, which indicates
decisive evidence in favor of the direct signaling of CD137 over T
cells.
Discussion
Mathematical models have been used to formulate hypotheses
and theories and make predictions regarding both the immune
response and M.tb infection that have previously posed a challenge
with traditional experimental methods [54,55]. In this paper, we
set a different aim: to integrate the information contained in
a particular experimental series with the previous knowledge by
applying a Bayesian analysis. For this purpose, we developed
a Bayesian Computational Model that simulated a set of previous
experimental data to analyze the effect of CD137 signaling
pathway during the human immune response against M.tb [15].
This BCM successfully fitted all the measured data and provided
new information about many relevant biological parameters and
complete kinetic profiles of the experimental variables. Moreover,
the simulation results allowed us to postulate a mechanism
responsible for the cytokine modulation by CD137.
BCM is made of two sets of equations: 1) a list of differential
equations describing the initial state and the evolution of the
underlying model, 2) a list of equations relating the state of the
model with observable quantities. At the same time, BCM receives
two kinds of inputs: 1) the prior distribution of parameters of those
equations and 2) a set of experimental observations with their error
rates. Finally, it produces three outputs: 1) the posterior
distribution of the parameters, 2) probability distribution of the
possible outcomes of observed and unobserved variables and 3) the
evidence of the model.
FrequentistAs long as we avoid logical contradictions in the
statement of the hypothesis and use proper priors, application of
Bayes rule leads to valid conclusions irrespective of the sample size
[19]There are many benefits provided by the BCM approach.
First, it uses the prior knowledge present in the literature to
interpret the experimental results analyzed. Also, it computes the
Figure 8. Predictions of the alternative model with indirect regulation over TL. A, CD137 expression on T cells; B, IFN-c levels in media; C,
TL intracelulIar IFN-c expression. Curves represent the best fit of our mathematical model to the data. The median and the 50% of the predictive
posterior interval are shown. Means of experimental data are shown by triangles 6 SEM for each group (A, 7 individuals; B, 15 individuals; C, 16
individuals).
doi:10.1371/journal.pone.0055987.g008
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information present in the results that was not present in the prior
and, finally, it allows calculating the Bayes factors to assess the
odds of alternative models. The resulting distribution of param-
eters can be used as priors for the analysis of new experimental
results. In addition, the BCM allows incorporating new mechan-
isms: in this case, the data has to be re-analyzed under the new
mechanism and one should run a new MCMC to obtain the
evidence of the new model to compare it with alternative models.
Finally, MCMC explores extensively the posterior distribution of
the parameters for building the credible intervals of the parameters
and the posterior predictive intervals of the data. In this way,
spurious predictions that arise because of overfitting are averaged
out. Methods like MAP or Maximum Likelihood, which are
simpler and computationally cheaper, do not share this quality.
Other approaches share some but not all these possibilities. A
classical ODE stability analysis might be complementary to the
BCM approach as it would help to explain at least part of the
reduction in range that happens in the distribution of the posterior
parameters. However, this analysis is not designed to fit and
extract information from experimental data. This task would be
achieved by a classical non-linear least square fitting. Yet, this
method does not incorporate prior information in a clear way, nor
does it tolerate models with a smaller number of data than
parameters. Finally, without the initial estimate of the covariance
at or near the MAP, the MCMC method would not be able to
approximate the posterior distribution in a feasible time. This
estimate is a natural output of the MAP algorithm.
The system of ODE equations of the BMC is explicit and easy
to solve by the Euler method. Euler method is known to be
unstable when the time step duration is long enough for changes in
the state variables to be significant in a single step. Given the
nature of the simulated biological processes, we do not expect that
to be the case for the chosen time step (6 seconds), and therefore
expect the Euler method to be adequate. This expectation was
corroborated by the small difference found for this time step
between Euler and the fourth order Runge-Kutta methods.
LMA is a powerful technique that converges to a local
minimum or a saddle point. Local minimum can be identified
by having small values of both the gradient norm and the
parameter l. By starting at random points within the prior
distribution of the parameters we allow the possibility of starting at
the basin of attraction of the global minimum. By increasing the
number of random starting points we increase the probability of
finding the global minimum. Of 5000 random starts, 3 of them
ended up with a Sum of Squares that was smaller than any other
case, all the 3 with the same parameters values.
Our BCM is based on a large system of 17 coupled differential
equations with 77 parameters. A large number of parameters and
equations might be detrimental to the credibility of the model
since the possibility of a spurious fit increases. Conversely, a small
number of parameters and equations might not be enough to
appropriately describe the system. In this paper, we used a small
set of equations that describes the fundamental biological process
necessary to explain the results. Every equation and the prior
distribution of each parameter were based on the literature and
theoretical considerations. The system of differential equations was
built with the idea of reproducing the biological process that
generates the data. Therefore, we did not avoid intricate
dependencies between the APC, NK and T cells and cytokine
levels that would make more difficult to fit the data. Moreover, as
the values of parameters are constrained by their prior distribu-
tion, in principle there was no guarantee that a combination of
parameters values would fit the experimental data. In fact just by
fixing 4 parameters (the ones that describe CD137 direct signaling
on T cells) the system fails to attain a complete fit of the data.
Consequently, the sizeable number of equations and parameters
compared to the analyzed experimental data was not an
impediment for achieving valid results. Bayesian statistics is able
to reach conclusions that are valid within its theoretical framework
even in a suboptimal situation like the one we have dealt in this
work. Orthodox statistics, on the other hand, cannot deal with
small values of n. Such cases are simply passed over; since its focus
is on large n. But small n is frequently the only information
available. Fortunately, Bayesian analysis can deal with this
situation: if we avoid logical contradictions in the statement of
a problem and use proper priors, we can reach valid solutions [19].
Nevertheless, as the BCM is not based on the description of direct
measurements of molecular interactions, the validity of the
conclusions we reach about them are highly dependent on the
validity of the model assumptions.
In our study we analyzed how CD137:CD137L interactions
regulate cytokine secretion in different cell populations. Our
previous experimental data demonstrated that CD137 blockage
significantly augmented TNF-a production in PBMC at different
times [15]. In line with those results, the posterior distribution of
the parameters revealed that CD137 signaling in APC inhibited
TNF-a production and enhanced apoptosis.
In agreement with the previous data, simulations demonstrated
that blocking the CD137 pathway early significantly augmented
IFN-c production, while blocking this pathway late resulted in
decreased cytokine secretion. We have previously hypothesized
that CD137 signaling diminished IFN-c production in NK cells at
the early time points of M.tb Ag-stimulation and, later during the
immune response augmented IFN-c levels and T cell effector
functions through the interaction between T cells and APC. Our
simulations support this hypothesis. The posterior distribution of
the parameters reveals that the mechanism for regulating TL
cytokine production is based on the survival effect of the pathway
more than on the inhibition of IFN-c production. A simplified
model that excluded direct TL could not fit the data on CD137
blockade effects on IFN-c production and survival of T cells. Bayes
Factor indicated decisive evidence for including the direct CD137
signaling in T cells. We therefore propose that the CD137
pathway regulates the mhomeostasis of cytokine levels required by
the host to combat M.tb infection at different stages of the immune
response.
Anti-CD137 antibodies are powerful immune modulators and
have demonstrated promise in the therapeutic mouse models of
cancer, viral disease, and autoimmunity. Moreover, phase I and II
clinical trials using anti-CD137 therapy for advanced cancers are
underway [56]. By performing Bayesian analysis of experimental
data that included blocking mAbs, we obtained details about of the
role CD137/CD137L pathway in regulating the immune response
during active tuberculosis. We hope that this work will contribute
to show how systems biology can be applied with experimental
data in the design of pathways signaling and of therapeutics.
Moreover, the results of our work may be used to design and
evaluate animal knock out models of CD137 signaling and
therapy. Nonetheless, caution must be used when designing ways
to manipulate CD137 in human therapy, given that the agonistic
anti-CD137 antibodies can cause severe immune system abnor-
malities [13,56] and taking into consideration the fact that the
CD137:CD137L pathway may operate differently in distinct cells
during the innate and adaptive immune response.
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Supporting Information
Figure S1 Reduction in the uncertainty of model
parameters that describe proliferation rates of each
cell. Bayesian analysis on the experimental data reduced the
uncertainty of the BCM parameter values. Gray areas represent
ranges containing 50% of the prior parameter distribution. Black
areas represent ranges containing 50% of the posterior parameter
distribution. For a description of parameters see table S1 in
Supporting Information S1.
(PDF)
Figure S2 Reduction in the uncertainty of model
parameters that describe death of each cell. Bayesian
analysis on the experimental data reduced the uncertainty of the
BCM parameter values. Gray areas represent ranges containing
50% of the prior parameter distribution. Black areas represent
ranges containing 50% of the posterior parameter distribution. For
a description of parameters see table S1 in Supporting Information
S1.
(PDF)
Figure S3 Reduction in the uncertainty of model
parameters that describe cytokine production rate by
each cell. Bayesian analysis on the experimental data reduced
the uncertainty of the BCM parameter values. Gray areas
represent ranges containing 50% of the prior parameter
distribution. Black areas represent ranges containing 50% of the
posterior parameter distribution. For a description of parameters
see table S1 in Supporting Information S1.
(PDF)
Figure S4 Reduction in the uncertainty of model
parameters that describe ratios of cytokine producing
cells. Bayesian analysis on the experimental data reduced the
uncertainty of the BCM parameter values. Gray areas represent
ranges containing 50% of the prior parameter distribution. Black
areas represent ranges containing 50% of the posterior parameter
distribution. For a description of parameters see table S1 in
Supporting Information S1.
(PDF)
Figure S5 Reduction in the uncertainty of model
parameters that describe ratios of receptor/ligand
expressing cells. Bayesian analysis on the experimental data
reduced the uncertainty of the BCM parameter values. Gray areas
represent ranges containing 50% of the prior parameter
distribution. Black areas represent ranges containing 50% of the
posterior parameter distribution. For a description of parameters
see table S1 in Supporting Information S1.
(PDF)
Figure S6 Reduction in the uncertainty of model
parameters that describe ratios of cell populations.
Bayesian analysis on the experimental data reduced the un-
certainty of the BCM parameter values. Gray areas represent
ranges containing 50% of the prior parameter distribution. Black
areas represent ranges containing 50% of the posterior parameter
distribution. For a description of parameters see table S1 in
Supporting Information S1.
(PDF)
Figure S7 Reduction in the uncertainty of model
parameters that describe antigen or antibody bindings.
Bayesian analysis on the experimental data reduced the un-
certainty of the BCM parameter values. Gray areas represent
ranges containing 50% of the prior parameter distribution. Black
areas represent ranges containing 50% of the posterior parameter
distribution. For a description of parameters see table S1 in
Supporting Information S1.
(PDF)
Figure S8 Reduction in the uncertainty of model
parameters that describe saturation constants. Bayesian
analysis on the experimental data reduced the uncertainty of the
BCM parameter values. Gray areas represent ranges containing
50% of the prior parameter distribution. Black areas represent
ranges containing 50% of the posterior parameter distribution. For
a description of parameters see table S1 in Supporting Information
S1.
(PDF)
Figure S9 Reduction in the uncertainty of model
parameters that describe cell association. Bayesian
analysis on the experimental data reduced the uncertainty of the
BCM parameter values. Gray areas represent ranges containing
50% of the prior parameter distribution. Black areas represent
ranges containing 50% of the posterior parameter distribution. For
a description of parameters see table S1 in Supporting Information
S1.
(PDF)
Figure S10 Reduction in the uncertainty of other model
parameters. Bayesian analysis on the experimental data
reduced the uncertainty of the BCM parameter values. Gray
areas represent ranges containing 50% of the prior parameter
distribution. Black areas represent ranges containing 50% of the
posterior parameter distribution. For a description of parameters
see table S1 in Supporting Information S1.
(PDF)
Supporting Information S1 Equations and table that
describe the model and the model parameters. Equations
S1–S5, S6–10 and S10–S14 describe the dynamics of APC, NK
and T cells respectively. Additional equations are used to relate the
system variables with the expected value for each experimental
data: the percentage of receptor/ligand expression for the included
types of cells, the levels of IFN-c and TNF-a in the media culture,
the percentage of IFN-c and or TNF-a-secreting cells, the
apoptosis for T-cells and the rate of [3H]TdR incorporation by
PBMC. Table S1 in Supporting Information S1 include a list of
the parameter names, descriptions, units and prior and posterior
parameters distribution. Parameters distributions are presented in
ranges.
(DOCX)
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